BAE-SYSTEMS
16.12.2022 10:02:34 CET | Business Wire | Press release
Sweden, Germany, and the United Kingdom have reached an agreement with BAE Systems to purchase 436 BvS10 all-terrain vehicles. The joint procurement, worth $760 million, is in support of Arctic operations for the Collaborative All-Terrain Vehicle (CATV) program.
BAE Systems’ military all-terrain vehicles are designed for operations in the harshest and most remote environments and this agreement signals the Company’s position as the defense industry’s leader for these capabilities.
“We‘re seeing increased interest from numerous countries for the extreme mobility capabilities offered by the BvS10 and its unarmored sister vehicle, Beowulf,” said Tommy Gustafsson-Rask, managing director of BAE Systems Hägglunds, which manufactures the vehicles in Örnsköldsvik, Sweden. “Sweden, Germany, and the United Kingdom will be getting an excellent return on their investment in these highly capable vehicles for decades to come. This further demonstrates the strong relationship between BAE Systems and our customers to deliver these critical capabilities.”
The three-nation acquisition will deliver the 436 vehicles beginning in 2024, with 236 BvS10s going to the Swedish Defense Materiel Administration (FMV), 140 to the German Federal Ministry of Defence (BAAINBw), and 60 to the United Kingdom Ministry of Defence (MoD). The vehicles are based on the latest version of the BvS10 currently operated by Sweden, and will include variants for troop transport, logistics, medical evacuation, recovery, and command and control.
The CATV program includes a framework agreement that could lead to the purchase of more vehicles by the three nations, keeping the BvS10, the world’s leading all-terrain vehicle, in production for many years to come. Sweden is the lead nation and has established a joint procurement office to lead the effort with representatives from all three nations.
This acquisition follows Sweden’s order last year of an additional 127 BvS10 all-terrain vehicles for its existing fleet. In parallel to this agreement, Sweden is also procuring an additional 40 BvS10s in a separate contract valued at approximately $50 million.
The BvS10 and Beowulf are the world leaders when it comes to all-terrain solutions. Their articulated mobility systems provide optimal maneuverability across varying terrains so they can traverse snow, ice, rock, sand, mud or swamps, as well as steep mountain environments. The vehicles’ amphibious feature also allow them to swim in flooded areas or coastal waters.
The vehicles can deliver personnel and supplies to sustain strategic, tactical, and operational mobility.
BvS10’s unprecedented mobility is based on terrain accessible North Atlantic Treaty Organization (NATO) standards. Its modular design allows it to be reconfigured for varying missions and can be delivered in multiple variants that include carrying personnel, command and control, ambulance, vehicle repair and recovery, logistics support, situational awareness, and a weapons carrier with additional mortar capability.
BvS10 is currently operated by Austria, France, the Netherlands, Sweden, and the United Kingdom. BAE Systems’ Beowulf, the unarmored variant of the BvS10, won the U.S. Army’s competition for its Cold Weather All-Terrain Vehicle (CATV) program in August. The U.S. Army will receive 110 vehicles over a five-year period.
Issued by:
BAE Systems, Inc.
www.baesystems.com
@BAESystemsInc
For associated imagery, please visit: https://baesys.resourcespace.com/?c=16201&k=d788ec24d8
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221216005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
